曲美他嗪预处理对不稳定型心绞痛介入治疗患者心肌损伤及血清Hcy、hs-CRP、NT-proBNP表达的影响
2019-08-07孙广慧
孙广慧


【摘要】 目的:探討曲美他嗪预处理对不稳定型心绞痛介入治疗患者心肌损伤及血清同型半胱氨酸(Hcy)、高敏C反应蛋白(hs-CRP)、N-端脑利钠肽前体(NT-proBNP)表达的影响。方法:收集本院2016年1月-2018年9月收治的64例接受经皮冠状动脉介入(PCI)治疗的不稳定型心绞痛患者,按随机数字表法分为两组,各32例。对照组术前给予常规药物治疗,观察组增加曲美他嗪行预处理。术前及术后18 h,检测并比较两组心肌肌钙蛋白I(cTnI)及血清Hcy、hs-CRP、NT-proBNP水平,术后6个月,检测并比较两组心功能。结果:术后18 h,观察组血清cTnI水平为(0.12±0.02)μg/L明显低于对照组(1.29±0.10)μg/L,差异有统计学意义(P<0.05)。术后18 h,观察组血清Hcy、hs-CRP、NT-proBNP水平分别为(20.30±2.45)μmol/L、(7.26±0.47)mg/L、(774.22±30.37)pg/mL,均明显低于对照组的(25.61±2.81)μmol/L、(9.22±0.62)mg/L、(850.61±35.02)pg/mL,差异均有统计学意义(P<0.05)。术后6个月,观察组LVESD为(31.05±3.27)mm明显低于对照组(34.46±3.63)mm,LVEF为(66.43±7.02)%明显高于对照组(62.05±5.89)%,差异均有统计学意义(P<0.05)。结论:不稳定型心绞痛患者介入治疗前给予曲美他嗪预处理,可减轻心肌损伤及机体炎症反应,改善心功能。
【关键词】 曲美他嗪; 不稳定型心绞痛; 经皮冠状动脉介入治疗; 心肌损伤; 心功能
【Abstract】 Objective:To investigate the effects of Trimetazidine preconditioning on myocardial injury and serum homocysteine(Hcy),high-sensitivity C-reactive protein(hs-CRP)and N-terminal brain natriuretic peptide(NT-proBNP)expression in patients with unstable angina pectoris.Method:64 patients with unstable angina pectoris underwent percutaneous coronary intervention(PCI)were enrolled in our hospital from January 2016 to September 2018.According to the random number table method,they were divided into two groups,32 cases in each group.The control group was given conventional medication before surgery,and the observation group was given pretreatment with Trimetazidine.The cardiac troponin I(cTnI),Hcy,hs-CRP,and NT-proBNP levels in two groups were measured and compared before and 18 h after surgery.Heart function in two groups was detected and compared 6 months after surgery.Result:At 18 h after operation,the level of serum cTnI in the observation group [(0.12±0.02)μg/L] was lower than that of the control group [(1.29±0.10)μg/L],the difference was statistically significant(P<0.05).At 18 h after operation,the levels of serum Hcy,hs-CRP and NT-proBNP in the observation group were(20.30±2.45)μmol/L,(7.26±0.47)mg/L,(774.22±30.37)pg/mL,lower than(25.61±2.81)μmol/L,(9.22±0.62)mg/L,(850.61±35.02)pg/mL in the control group,the differences were statistically significant(P<0.05).At 6 months after operation,the LVESD of the observation group [(31.05±3.27)mm] was lower than that of the control group [(34.46±3.63)mm],and the LVEF [(66.43±7.02)%]was higher than that of the control group [(62.05±5.89)%],the differences were statistically significant(P<0.05).Conclusion:Pretreatment with Trimetazidine before PCI in patients with unstable angina pectoris can reduce myocardial injury and inflammatory response,improve cardiac function.
【Key words】 Trimetazidine; Unstable angina pectoris; Percutaneous coronary intervention; Myocardial injury; Cardiac functionFirst-authors address:Jiamusi Hospital of Traditional Chinese Medicine,Jiamusi 154002,China
doi:10.3969/j.issn.1674-4985.2019.15.011
不稳定型心绞痛是由冠状动脉粥样硬化、冠状动脉栓塞、炎症等引起管腔狭窄,血流受阻,造成心肌供血不足所致,是冠心病的一种急性心脏事件,以胸部不适或者胸痛等为临床主要症状表现[1-2]。当前,经皮冠状动脉介入术(PCI)是治疗该病的常用方法,可有效疏通狭窄的冠状动脉,恢复心肌血流灌注[3]。但PCI术中球囊机械性向外挤压狭窄的冠状动脉腔,必然会引起血管壁损伤、心肌损伤,加重局部炎性反应。数据显示,PCI围术期心肌损伤发生率达30%~40%,其为影响患者预后的一个独立危险因素[4]。因而寻求具有心肌保护作用的药物意义重大。
曲美他嗪属于哌嗪类的一种衍生物,具有抗心肌缺血、增强心肌收缩功能的作用[5]。……
